Toggle search
Toggle menu
406
21
32
6.1K
Pharmacopedia
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Drilldown: Medicines

More actions

Choose a table:


Medicines > classes : Dissociative or Phenethylamine or SSRI

Use the filters below to narrow your results.

generic:
brand:
None (42) · DXM (1) · DXO (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Spravato (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Very potent 5-HT2A agonist; long duration (1)
uses:
None (46) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (45) · 25 mg (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (45) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (45) · 200 mg/d (1) · 84 mg per session (1)
routes:
None (44) · insufflated (1) · Intranasal (under direct medical supervision) (1) · Oral (2) · PR (1)
onset:
None (44) · 45-75 min (oral) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Within hours of first administration (1)
duration:
None (44) · 4-8 h (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Long (1)
halflife:
None (44) · Not well characterized (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7-12 hours (1)
bioavailability:
None (44) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not well characterized (1) · ~48% intranasal (1)
pregnancy:
None (44) · Avoid; may cause fetal harm (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Not established (1)
legal:
None (44) · Rx, Schedule III (US). REMS program required. (1) · Rx-only in US (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 47 results in range #1 to #47.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"